ClinConnect ClinConnect Logo
Search / Trial NCT00705757

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Launched by SUMMA HEALTH SYSTEM · Jun 25, 2008

Trial Information

Current as of July 21, 2025

Completed

Keywords

Periocular Skin Pigmentation Lumigan Travatan Xalatan Latanoprost Bimatoprost Travoprost

ClinConnect Summary

One uncommon side effect of prostaglandin eye drops is a change in color of the skin around the eyes, which is reversible. There are three different brands of the medicine which are equally effective in lowering eye pressure but their likelihood of changing skin color is unknown. Qualifying patients will be randomly assigned to use one of the three eye drops. We will take skin color measurements from several locations on the face over one year to measure pigmentation changes.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • patients recently diagnosed with primary open angle glaucoma or ocular hypertension
  • Caucasian and African American ethnicities
  • Male and Female
  • Age 30 and above
  • Exclusion Criteria:
  • A history of ocular medication use within the last 12 months
  • Inflammatory/ allergic skin diseases or dermatitis
  • presence of periocular hyperpigmented skin lesions
  • Systemic pigmentation disorders
  • Use of systemic drugs that can affect skin pigmentation
  • Visitation of tanning salons, or use of self tanning products
  • Pregnancy or patients planning to become pregnant in the near future

About Summa Health System

Summa Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence, Summa Health System integrates cutting-edge technology and evidence-based practices to drive research initiatives across various therapeutic areas. The organization prioritizes patient safety and ethical standards while fostering collaboration among healthcare professionals, researchers, and participants. Through its robust clinical trial program, Summa Health System aims to contribute to the discovery of new treatments and therapies, ultimately enhancing the quality of care for the communities it serves.

Locations

Akron, Ohio, United States

Arlington Heights, Illinois, United States

Patients applied

0 patients applied

Trial Officials

Deepak P Edward, MD

Principal Investigator

Summa Health System

Smajo Osmanovic, MD

Principal Investigator

Arlington eye Associates

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials